Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "pharma"


25 mentions found


The hard-fought settlement of thousands of lawsuits against Purdue Pharma was close to capsizing on Thursday, after the Supreme Court rejected liability protections for the company’s owners. The ruling effectively prevents the release of billions of dollars that could help alleviate the ravages of opioid addiction. The future of the cases, some of which are a decade old, is now in limbo, as states, local governments, tribes and more than 100,000 individuals who sued the company, best-known for its prescription painkiller OxyContin, figure out next moves. The court effectively upended the settlement by striking down a provision that Purdue’s owners, members of the billionaire Sackler family, had insisted upon: immunity from all current and future opioid lawsuits in return for payments of up to $6 billion to plaintiffs. In a statement, Purdue called the decision “heart-crushing,” because the settlement had been agreed to by an overwhelming majority of plaintiffs.
Persons: Sackler Organizations: Purdue Pharma, Purdue Locations: capsizing
The Supreme Court ruled on Thursday that members of the wealthy Sackler family cannot be shielded from lawsuits over their role in the opioid crisis as part of a bankruptcy settlement that would channel billions of dollars to victims and their families. In a 5-to-4 decision, written by Justice Neil M. Gorsuch, a majority of the justices held that the federal bankruptcy code does not authorize a liability shield for third parties in bankruptcy agreements. Justice Gorsuch was joined by Justices Clarence Thomas, Samuel A. Alito Jr., Amy Coney Barrett and Ketanji Brown Jackson. In a strongly worded dissent, Justice Brett M. Kavanaugh wrote that the “decision is wrong on the law and devastating for more than 100,000 opioid victims and their families.” He was joined by Chief Justice John G. Roberts Jr. and Justices Sonia Sotomayor and Elena Kagan. The decision jeopardizes a carefully negotiated settlement Purdue and the Sacklers had reached in which members of the family promised to give up to $6 billion to states, local governments, tribes and individuals to address a devastating public health crisis.
Persons: Sackler, Justice Neil M, Gorsuch, Clarence Thomas, Samuel A, Alito Jr, Amy Coney Barrett, Ketanji Brown Jackson, Brett M, Kavanaugh, John G, Roberts Jr, Sonia Sotomayor, Elena Kagan Organizations: Chief, Purdue
As the nation continues to grapple with the opioid epidemic, the Sackler family had agreed to pay $6 billion to families and states as part of an agreement to wind down Purdue Pharma, the maker of OxyContin. In exchange, the Sackler family would be immunized from future civil liability claims. Those supporting the bankruptcy argued the yearslong process had gone on long enough and was unlikely to yield additional money from the Sackler family. The vast majority of known current opioid victims and their families supported the agreement. But the Justice Department said it was a raw deal for victims – particularly potential future victims.
Persons: Sackler, Neil Gorsuch, ” Gorsuch, , ” Kavanaugh, , John Roberts, Sonia Sotomayor, Elena Kagan Organizations: Washington CNN, Chief, Congress, Purdue Pharma, Department Locations: New York
The iShares U.S. Pharmaceuticals ETF (IHE) is up 9% since July 2015, when it hit a fresh all-time high. All of the back-and-forth movement since 2015 has produced what could be a monstrous bullish pattern. But we're trying to capture a major breakout from an area that's done next to nothing in nearly a decade. INVA, on the other hand, bottomed in March 2023, and just recently broke out of a large inverse head & shoulders pattern. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR.
Persons: IHE, Eli Lilly, Johnson, JNJ, MRK, Frank Cappelleri Organizations: U.S . Pharmaceuticals, IHE, Merck, CNBC, NBC UNIVERSAL Locations: U.S, LLY
U.S. President Joe Biden delivers remarks alongside Treasury Secretary Janet Yellen and Commerce Secretary Gina Raimondo during a Cabinet Meeting at the White House on June 06, 2023 in Washington, DC. President Joe Biden's Cabinet will wrap up a barnstorming tour Thursday after two weeks on the road, touting the administration's economic accomplishments ahead of the Democratic incumbent's first debate against former President Donald Trump. In the 10 days leading up to Thursday's debate, the White House organized 29 public events, featuring more than a dozen top administration officials to promote Biden's economic agenda, a White House official said in a memo announcing the blitz. Not anymore," Neera Tanden, White House domestic policy advisor, said in the release. "Thanks to President Biden's economic plan, the American economy is strong and resilient, with robust economic growth in recent quarters," she said in a speech Monday.
Persons: Joe Biden, Janet Yellen, Gina Raimondo, Joe Biden's, Donald Trump, Lael Brainard, Pete Buttigieg, Neera Tanden, Yellen, Biden's Organizations: White House, Democratic, White, National Economic, Transportation, Seniors Locations: Washington , DC, Georgia , Nevada , Pennsylvania, Michigan, White, Minnesota, American
Cramer’s Stop Trading: Alnylam Pharma
  + stars: | 2024-06-24 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCramer’s Stop Trading: Alnylam PharmaCNBC’s Jim Cramer explains why he is keeping an eye on shares of Alnylam Pharma.
Persons: Jim Cramer Organizations: Alnylam, Alnylam Pharma
Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024. LONDON — Shares of Denmark's Zealand Pharma popped nearly 23% in Friday morning deals, notching a record high after an early-stage study of its weight loss drug challenger produced positive results. Petrelintide was "judged to be safe and well tolerated at all dose levels" and the results provided "robust support" for its potential as an alternative to GLP-1 receptor agonist-based therapies for weight management, Zealand Pharma said in a release. GLP-1RA-based treatments include Ozempic, the diabetes drug produced by fellow Danish pharmaceutical firm Novo Nordisk , which has exploded in popularity globally for its weight-loss effects. Soaring demand for Ozempic and obesity drug Wegovy have propelled Novo Nordisk to become Europe's most valuable company.
Persons: Petrelintide Organizations: Novo Nordisk, Denmark's Zealand Pharma, Zealand Pharma Locations: Hillerod, Denmark, Danish
Final Trades: Nvidia, Abbvie, ConocoPhillips and Vertex Pharma
  + stars: | 2024-06-14 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Nvidia, Abbvie, ConocoPhillips and Vertex PharmaThe Investment Committee share their top stocks to watch for the second half.
Organizations: Nvidia, Abbvie, ConocoPhillips, Vertex Pharma, Investment
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMadrigal Pharma CEO talks competition in the GLP-1 space and new drug rolloutsBill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk GLP-1 drug competition, its liver disease treatment, its Mash drug rollout and more.
Persons: Bill Sibold Organizations: Madrigal, Madrigal Pharma
The spotlight has seemingly shifted in the past year toward companies going to market, hoping to ride on the coattails of India's growth story. Growing foreign listingsThe allure of India's stock markets has trickled to companies beyond its shores — with foreign entities eyeing a share of its growth. Such listings add strength to India's markets, says M&G Investment's Asian Equities Portfolio Manager Vikas Pershad. The optimism on India's IPO boom is sometimes marred by concerns over elevated valuations of its stock market — and whether it is headed toward a bubble. "When we look at India, we see continued economic and earnings per share growth and higher levels of profitability," Dorson from Global X told CNBC's Inside India.
Persons: Swiggy, Debarchan Chatterjee, Neil Bahal, Dhruba Jyoti Sengupta, Ola, PhonePe, Ola Electric, Sengupta, Vikas Pershad, Malcolm Dorson, CNBC's Organizations: Getty, Reliance Industries, Adani Enterprises, Mankind Pharma, Negen, Securities, Exchange Board, Wrise Private, Aakash Educational Services, Aakash Educational, Walmart, United Arab, Hyundai, Insurance Corporation of India, Maruti Suzuki, Hindustan Unilever, Siemens, ABB India, Global Locations: Kolkata, India, SEBI, United Arab Emirates, Sri Lanka, Hyundai India, India's, Maruti Suzuki India, Hindustan
Read preview"Pharma bro" Martin Shkreli has been accused in a lawsuit of making and sharing copies of a supposedly one-of-a-kind Wu-Tang Clan album before he sold it for $4.75 million. The Wu-Tang Clan album that was forfeited by Martin Shkreli, in a handout photo dated July 2021. UNITED STATES MARSHALS SERVICE/ReutersBut it went on to describe multiple alleged examples of Shkreli either playing the album on livestreams or bragging about how many copies he has. During one livestream, during which he is alleged to have played the album, Shkreli said, per the lawsuit: "Of course I made MP3 copies, they're like hidden in safes all around the world." In other comments cited in the lawsuit, Shkreli suggested he'd "sold" copies and that more than 5,000 people had copies.
Persons: , bro, Martin Shkreli, Wu, Tang, Shkreli, Wu - Tang Clan, PleasrDAO, he's Organizations: Service, Business, Wu -, Guardian, UNITED STATES, SERVICE
A federal judge temporarily barred notorious "pharma bro" Martin Shkreli from streaming or disseminating copies of a one-of-a-kind Wu-Tang Clan album he had forfeited as part of his criminal fraud conviction in 2017. Steven Cooper, a lawyer for PleasrDAO, said Wednesday that he could not comment on whether he has been in touch with prosecutors on Shkreli's alleged violation of his forfeiture order. Shkreli bought the Wu-Tang Clan album in 2015 for $2 million, setting a Guinness world record for the most expensive musical work ever sold. The 31-track, two-disc Wu-Tang Clan album, came in a hand-carved, nickel-and-silver-cased box set, which itself was nestled in a larger leather box. At the time of the sale, Shkreli owed almost $2.4 million on the forfeiture order.
Persons: Martin Shkreli, Benjamin Brafman, bro, Martin, Wu, Tang, Pamela Chen, Shkreli, Chen, Steven Cooper, PleasrDAO, Cooper, Lil Wayne, Carter, Pablo Picasso, Wu - Tang Organizations: U.S, CNBC, pharma, Wu - Locations: Brooklyn, New York City, U.S, Brooklyn , New York, Cayman Islands, Tasmania, Australia, United States
PAI Pharma COO on visibility and representation
  + stars: | 2024-06-05 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPAI Pharma COO on visibility and representationPAI Pharma COO Brandon Rockwell says in a world where visibility and representation matters, you never know who you could be influencing around you.
Persons: Brandon Rockwell Organizations: PAI Pharma, PAI
The withdrawal risk of quitting antidepressants
  + stars: | 2024-06-05 | by ( Kristen Rogers | ) edition.cnn.com   time to read: +7 min
Roughly 15% of participants who discontinued antidepressants experienced withdrawal symptoms such as dizziness, headaches, nausea, insomnia and irritability, according to the review published Wednesday in the journal The Lancet Psychiatry. The review is the first publication of a larger project on antidepressant withdrawal symptoms, the authors said. The authors also discovered the medications most often linked with withdrawal symptoms were desvenlafaxine, venlafaxine, imipramine and escitalopram. The rate of withdrawal symptoms in pharma-funded studies was about the same as trials not funded by pharmaceutical companies. The study didn’t provide information on the duration of withdrawal symptoms, but other research suggests they can last for up to two weeks in most cases, Keedwell said.
Persons: , Jonathan Henssler, ” Henssler, Sameer Jauhar, Jauhar wasn’t, ” Jauhar, Christiaan Vinkers, weren’t, Tony Kendrick, , ” Kendrick, Henssler, Jauhar, Oliver Howes, Howes wasn’t, Paul Keedwell, wasn’t, Keedwell, ” Keedwell Organizations: Lifeline, CNN, neurosciences, Charité — University Medicine, King’s College London, Pharmaceutical, pharma, Amsterdam University Medical Center, University of Southampton, Cleveland Clinic, Royal College of Psychiatrists Locations: United Kingdom, Berlin, England
Update: On Thursday the Supreme Court ruled 5 to 4 that the federal bankruptcy code does not shield members of the Sackler family from liability for civil claims stemming from the opioid crisis. The United States Supreme Court is now considering whether the bankruptcy system should have given this wealthy family a permanent shield against civil liability. But there is a bigger question at stake, too: Why is a company with no lenders turning to the federal bankruptcy system in response to accusations of harm and misconduct? The maker of OxyContin is one in a long line of companies that have turned Chapter 11 into a legal Swiss Army knife, tackling problems that are a mismatch for its rules. But Chapter 11 was designed around the goal of helping financially distressed businesses restructure loans and other contract obligations.
Persons: Sackler, Brett Kavanaugh Organizations: Purdue Pharma, United States, Swiss Army Locations: Swiss
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. LONDON — Shares of British pharmaceuticals giant GSK plunged 9% Monday, after a U.S. court ruled that scientific evidence could be presented in a stack of lawsuits relating to the discontinued heartburn drug Zantac. The Delaware State Court late on Friday ruled that plaintiffs' expert witnesses could testify in the roughly 75,000 cases alleging the once-popular drug ranitidine — sold under the brand name Zantac in the U.S. — may cause cancer. The companies involved deny there is a scientific consensus that the drug can be linked to any later development of cancers. In a statement Friday, GSK said it disagreed with the latest Delaware ruling and would immediately seek an appeal.
Persons: ranitidine —, Brent Wisner, Wisner Baum, Zantac Organizations: GlaxoSmithKline, Stevenage, GSK, Delaware State Court, France's, Pfizer, Germany's Locations: Britain, Delaware, U.S, France's Sanofi
The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs said. New products such as Eli Lilly's Zepbound prompted the bank to raise its forecast. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . AdvertisementThe market for weight-loss drugs such as Ozempic and Wegovy will keep surging due to new products including Eli Lilly's Zepbound, according to Goldman Sachs. In a research note the bank forecast that the sector will be worth $130 billion by 2030 — $30 billion higher than its previous projection.
Persons: Goldman Sachs, Eli Lilly's Zepbound, , Wegovy, Eli Lilly, Chris Shibutani Organizations: FDA, pharma, Service, Nordisk, Business Locations: Danish
An AI model that is trying to use machine learning to pick stocks is optimistic about the outlook for some names in volatile sectors over the next month. IFi AI is a company aimed at individual investors that identifies stocks with potential upside based on a blend of fundamental, technical and news data. The stock in the model's highest confidence bracket with the most projected upside is a similarly named company — Marathon Digital . But instead of being an energy company, Marathon Digital is a bitcoin miner. CNBC senior analyst and commentator Ron Insana is the CEO if iFi AI, which launched in March .
Persons: IBM's Watsonx, , Kilroy, Ron Insana Organizations: Marathon Oil, ConocoPhillips, Marathon, iFi, Kilroy Realty, BridgeBio Pharma, Viking Therapeutics, Therapeutics, CNBC Locations: California
Check out the companies making the biggest moves midday: GameStop — Shares jumped nearly 23% following the video game retailer's announcement on Friday that it made about $933 million from a stock sale. U.S. Cellular — Shares added 7% after the telecom company announced T-Mobile will acquire its wireless operations and 30% of spectrum assets for $4.4 billion. T-Mobile was up less than 1%, while Telephone and Data Systems , which owns 84% of U.S. Cellular, slipped 2%. Norwegian Cruise Line — The cruise stock rose 3% after an upgrade to buy from neutral at Mizuho. Zscaler — The cybersecurity company shed nearly 4% following a downgrade at Wells Fargo to equal weight from overweight.
Persons: Agios, vorasidenib, , Duolingo Max, Semler, Elon, Zscaler, Airbnb, Eli Lilly, Macheel, Pia Singh, Hakyung Kim, Jesse Pound Organizations: GameStop, . Illinois, U.S, Cellular, Mobile, Telephone, Data Systems, U.S . Cellular, . Food, Drug, Pharmaceuticals, Royalty Pharma, Nvidia, Cruise, Mizuho, Sarepta Therapeutics, RBC Capital Markets, RBC, Sea, Reuters, , Energy Capital Partners, Wedbush, FDA Locations: U.S, Norwegian, Wells
Wu-Tang Clan first announced in March 2014 that it would produce one copy of “Once Upon a Time in Shaolin” to be sold to the highest bidder. The album came in a hand-carved box with a leather-bound book of parchment paper containing lyrics and its backstory. The Wu-Tang Clan originated as a group of rappers from Staten Island, New York in the 1990s. In 2015, notorious “Pharma Bro” Martin Shkreli bagged the album for about $2 million – making it the world’s most expensive music album ever sold at the time. In 2021, the US Justice Department then sold the album without disclosing the buyer.
Persons: CNN —, , Wu, Jarrod Rawlins, , ” Rawlins, Tang, ” Wu, Robert “ RZA ” Diggs, Forbes, RZA, Tang Clan, Bob Berg, Pharma Bro ” Martin Shkreli, Shkreli, Jon Lynn, PleasrDAO Organizations: CNN, Museum, Mona, Tang Clan, Pharma, America ”, Turing Pharmaceuticals, US Justice Department, DoJ, New Art Digital, New York Times Locations: Tang, Tasmania, Staten Island , New York, Shkreli, America
A new generative AI tool can create those studies in minutes. That directive informed Atropos' development of ChatRWD, which Atropos Health launched in beta form in October to 75 customers. Atropos says it's the first generative AI tool to create publication-grade studies from clinical data in minutes. AdvertisementAtropos' $33 million Series B funding follows Atropos' $14 million Series A in August 2022, bringing the company's total funding to $54 million. See the 22-slide pitch deck Atropos Health used to raise $33 million in Series B funding.
Persons: , Brigham Hyde, Valtruis, Jim Breyer's Breyer, Laurene Powell Jobs, Nigam Shah, Saurabh, Hyde, Atropos, Green Button, Green, Johnson, Johnson's Janssen Organizations: Service, Business, Atropos, Cencora Ventures, McKesson Ventures, Merck GHI Fund, Presidio Ventures, Stanford University, National Institutes of Health, Atropos Health, pharma Locations: Geneva, Arcadia
A top exchange-traded fund provider is betting on the long-term popularity of GLP-1 weight loss drugs. Roundhill Investments' GLP-1 & Weight Loss ETF (OZEM), which began trading last week, pairs leaders Eli Lilly and Novo Nordisk with players developing new treatments for weight loss and diabetes. Eli Lilly and Novo Nordisk each hold a roughly 20% weighting in the ETF, per Roundhill's website as of Friday. Mazza waived concerns that investors have missed out on the rally, noting the weight loss drug industry is still in its "early days." After last Tuesday's launch, shares of Roundhill's GLP-1 & Weight Loss ETF ended the week down by almost 2%.
Persons: Eli Lilly, Dave Mazza, Mazza, CNBC's Organizations: Investments, Novo Nordisk, Zealand Pharma, Amgen, Chugai Pharmaceutical Locations: Roundhill's
The time may have finally come for small-cap stocks to have their moment in the sun, according to Jefferies. "We have seen some improvement in absolute and relative performance and think we could have hit an inflection point," wrote Jefferies strategist Steven DeSanctis. Still, he said there's one caveat: small-cap earnings look weak on an absolute basis. "As the year rolls along, small-cap earnings are set to broaden, accelerate, and play a game of catch-up with large." Jefferies' price target of $140 is nearly 32% higher than where shares of ArcBest closed on Thursday afternoon.
Persons: Jefferies, Steven DeSanctis, Schrodinger Organizations: Nvidia, Boston Beer, Boston, Software, pharma, . Trucking Locations: ArcBest
RBC Capital Markets sees a $25 billion market opportunity for the space. The average analyst rating is hold, with 8% upside to the average analyst price target, according to FactSet. Eli Lilly has an average analyst rating of overweight and 8.3% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon AstraZeneca's one-year performanceAstraZeneca shares have an average analyst rating of overweight and nearly 6% upside to the average analyst price target, according to FactSet. Stock Chart Icon Stock chart icon Bristol-Myers Squibb's one-year performance
Persons: It's, Gregory Renza, Renza, Oppenheimer, Jeff Jones, Piper Sandler, Edward Tenthoff, Eli Lilly, Dan Lyons, Janus Henderson, Myers Squibb, William Blair, Matt Phipps, Jefferies, Andrew Tsai, They've, Janus Henderson's Lyons, Jones, Piper Sandler's Tenthoff, Myers Organizations: pharma, RBC Capital Markets, TRT, Novartis, Mariana Oncology, Janus, Janus Henderson Investors, Bristol, RayzeBio, Karuna Therapeutics, AstraZeneca, Fusion Pharmaceuticals, GlobalData's Pharma Intelligence, Pluvicto Locations: Mariana, Bristol
Morgan Stanley accompanied the move by cutting its price target to $100 from $120. His $185 price target, up from $160, forecasts that shares of Take-Two could rally 23% from Wednesday's close. — Lisa Kailai Han 5:55 a.m.: Bernstein initiates Ford at an outperform rating Investors who don't own Ford are missing out, according to Bernstein. — Lisa Kailai Han 5:55 a.m.: JPMorgan upgrades Hasbro Don't expect Hasbro's momentum to slow in the near future, according to JPMorgan. It also raised its price target on shares to $74 from $61, implying upside of 22%.
Persons: Bernstein, Morgan Stanley downgrades NetEase, Morgan Stanley, Alex Poon, Poon, Lisa Kailai Han, Omar Dessouky, Dessouky, — Lisa Kailai Han, Sam Poser, Sean Dodge, Dodge, GoodRx, Ford, Daniel Roeska, Roeska didn't, Roeska, Christopher Horvers, Fred Imbert Organizations: CNBC, Ford, JPMorgan, Hasbro, NetEase, Bank of America, Rockstar Games, Rockstar, Supreme, Corp, Trading, EMEA, Timberland, RBC, RBC Capital Markets, pharma, Kroger Locations: China, Wednesday's, Americas
Total: 25